ARRY-371797, p38 inhibitor; oral
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
LMNA-Related Dilated Cardiomyopathy
Conditions
LMNA-Related Dilated Cardiomyopathy
Trial Timeline
Feb 1, 2014 → May 1, 2016
NCT ID
NCT02057341About ARRY-371797, p38 inhibitor; oral
ARRY-371797, p38 inhibitor; oral is a phase 2 stage product being developed by Pfizer for LMNA-Related Dilated Cardiomyopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT02057341. Target conditions include LMNA-Related Dilated Cardiomyopathy.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02057341 | Phase 2 | Completed |
Competing Products
1 competing product in LMNA-Related Dilated Cardiomyopathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ARRY-371797, p38 inhibitor, oral | Pfizer | Phase 2 | 51 |